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Summary
Inherited diseases of calcium homeostasis were described
more than 30 years ago. Consecutively, the discovery of the
calcium receptor (CaR) more than a decade ago, followed by
the demonstration that familial diseases of hyper- and hypocal-
cemia, in some cases were caused by functionally important
mutations in the CaR, highlighted the receptor's pivotal role in
the maintenance of systemic calcium homeostasis. Mutations
that change the receptor’s affinity toward calcium induce ill-
nesses of calcium homeostasis by changing the set-point for
calcium-regulated PTH release as well as the renal handling of
calcium. Gain-of-function mutations cause a form of autoso-
mal dominant hypoparathyroidism (ADH); this rare disease ex-
hibits a clinical spectrum from mild to much more severe and
symptomatic hypocalcemia with relative or absolute hypercal-
ciuria. Loss-of-function mutations produce PTH-dependent
forms of hypercalcemia called familial hypocalciuric hypercal-
cemia (FHH) in their heterozygous state (one mutated allele)
and neonatal severe primary hyperparathyroidism (NSPHT) in
their homozygous or compound heterozygous forms (two mu-
tated alleles). FHH is thought to occur with about 1% of the
prevalence of primary hyperparathyroidism and is often a be-
nign state of hypercalcemia with relatively low urinary calcium
output. NSPHT, on the other hand, is a considerably more rare
but severe form of hypercalcemia presenting in most cases
during the first 6 months of life. Affected children become
symptomatic early on in life with failure to thrive and severe
hyperparathyroid bone disease and may even die if left un-
treated. Until recently treatment of this condition involved to-
tal or subtotal parathyroidectomy. Similar to the inherited dis-
eases with mutations in the calcium-sensing receptor, autoim-
mune diseases with antibodies targeting the CaR have been
recognized. This review will focus on the calcium-sensing re-
ceptor, including its molecular physiology, as well as its role
in various diseases of calcium homeostasis that illuminate the
receptor’s role not only in pathophysiology but also in normal
physiology. Lastly, we shall describe the CaR as a drug target
with proven and potential applications.
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Introduction
The calcium-sensing receptor (CaR) is a widely-expressed,
seven transmembrane receptor (7TM receptor – also termed G
protein-coupled receptor) (1). Its main function lies in the chief
cells of the parathyroid gland. Here the CaR regulates the syn-
thesis and secretion of parathyroid hormone (PTH). PTH is the
most important hormone in the acute regulation of the extracel-
lular ionic calcium concentration (Ca2+o). Ca2+o is maintained
within a narrow range (1.1-1.3 mM). Both very high and very
low levels of Ca2+o are dangerous and can be life-threatening.
Minute changes in Ca2+o, in the range of a few percent, lead to
immediate physiologic responses, including altered PTH secre-
tion, that restore the level of Ca2+o to normal. Rapid changes in
Ca2+o are more dangerous than slowly developing ones; there-
fore, the rapidity of the PTH response is essential. The CaR,
cloned more than a decade ago, is a key player in this delicate
process of calcium homeostasis (1). The CaR acts like a ther-
mostat, but instead of measuring changes in temperature, it
measures alterations in the level of Ca2+o, thereby functioning
as a “calciostat” and informing the chief cells of the parathyroid
glands of the exact level of Ca2+o. The parathyroid glands re-
spond to changes in Ca2+o with CaR-mediated alterations in
PTH secretion. 
The calcium-sensing receptor was cloned using the widely ex-
ploited expression-cloning technique (1). Subsequent analysis
of the receptor’s structure and alignment of it with protein data-
bases have situated the CaR within family C of the superfamily
of seven transmembrane receptors. Other important receptors
within this family are the metabotropic receptors for glutamate
(mGluRs) and gamma-aminobutyric acid (GABA), as well as
receptors for pheromones and odorants (in fish). And recently
an orphan receptor, GPRC6A, has been found to resemble the
CaR in several of its pharmacological properties (2). This re-
ceptor, like the CaR, is sensitive towards certain L-amino
acids, although unlike the CaR, which senses aromatic amino
acids most effectively, GPRC6A is a sensor of basic amino
acids (3). It was subsequently shown that this receptor is also
sensitive towards extracellular calcium (albeit at high concen-
trations) and calcimimetics (4), allosteric activators of the CaR,
which may implicate GPRC6A as a second calcium-sensing re-
ceptor (CaSR2). 
The physiological importance of the calcium-sensing receptor
in humans was proven by the discovery of diseases caused by
mutations in the receptor that lead to either loss-of-function or
gain-of-function (5). Heterozygous (e.g., the mutation is pre-
sent in only one allele and the other allele carries wild type
CaR) gain-of-function mutations cause autosomal dominant
hypoparathyroidism (ADH). Most patients have asymptomatic
hypocalcemia with relative or absolute hypercalciuria. Het-
erozygous loss-of-function mutations give rise to familial
hypocalciuric hypercalcemia – FHH, also termed familial be-
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nign hypocalciuric hypercalcemia (FBHH) by some – in which
most patients have an asymptomatic form of hypercalcemia
with relative or absolute hypocalciuria. The homozygous or
compound heterozygous variant of inactivating CaR mutations,
on the other hand, produce neonatal severe primary hyper-
parathyroidism (NSHPT), a severe, sometimes deadly disease
if left untreated. The mouse models of FHH (heterozygous in-
activation of the CaR gene) and NSHPT (homozygous loss of
the CaR) have phenotypes comparable to those of the respec-
tive human conditions, suggesting that the number of receptors
on the cell surface is in some cases the determining factor for
clinical expression of the disease. Thus one way in which the
mutated receptors may exert their effects on calcium home-
ostasis is through a reduced level of expression of wild type re-
ceptors, as in the heterozygous knock out mice. Another way
reflects the fact that the receptor normally functions as a dimer,
such that heterodimerization of some mutant receptors with
their respective wild type partner exerts a dominant negative
action on the latter. 
CaR expression is highest in the parathyroid glands, calcitonin-
secreting C-cells of the thyroid gland, and kidney, but the CaR
is also present in the two other organs involved in calcium
homeostasis: gut and bone. This review will focus on the calci-
um-sensing receptor and its role in normal physiology as well
as in disease states that illuminate not only pathophysiology
but also normal calcium homeostasis as well. 
Biochemical and physiological features of the CaR
To provide the reader of this review with sufficient background
to understand how mutations in the CaR cause disease, a brief
introduction to the structure of the receptor and its downstream
signaling pathways is provided. Then, in this section of the re-
view, we review the functions that the CaR plays in normal cal-
cium homeostasis. Lastly we will provide an update on the top-
ic of naturally occurring and pharmacologic ligands to the re-
ceptor.
Structure and signal apparatus
The CaR was isolated by utilizing the expression cloning tech-
nique in Xenopus laevis oocytes to secreen a bovine parathy-
roid cDNA library. A 5.3-kb clone was isolated in this manner
that showed, when expressed in the oocytes, the same phar-
macological properties as the Ca2+o-sensing apparatus in dis-
persed bovine parathyroid cells (1). Soon after, standard use of
nucleic acid hybridization permitted the cloning of the CaR in
humans (6, 7), rats (8), mice (9), and rabbits (10). The nucleic
acid sequences of the receptors are at least 85% identical to
that of the original bovine parathyroid CaR. The amino acid se-
quences exhibit even greater homology [>90% identity using
http://www.ncbi.nlm.nih.gov/BLAST/]. Thus functionally impor-
tant mutations in the receptor have most likely been discarded
through evolution. 
The CaR belongs to family C II of the superfamily of seven
transmembrane (7TM) receptors, also termed G protein-cou-
pled receptors (11). 7TM receptors are the largest group of cell
surface membrane receptors. They are very important in clini-
cal medicine, as the 7TM receptors are the targets of about
50% of currently available medications. The human CaR is
1078 amino acid residues long. The receptor has three struc-
tural domains, like all 7TM receptors (Fig. 1): The CaR has an
unusually large extracellular domain (ECD), the hydrophobic
N-terminal end of 612 residues; a transmembrane domain
(TMD) of 250 amino acids containing the 7 membrane span-
ning helices, and an intracellular domain (ICD) 216 amino
acids long, which is the hydrophilic C-terminal end of the pro-
tein. The receptor is modified by N-linked glycosylation; this is
important for the cell membrane expression of the receptor. On
the cell membrane the CaR is primarily in a dimeric form, and
the two receptor monomers are linked by covalent disulfide
bonds involving two cysteine residues in each monomer
(cys129 and cys131) (12-14). The location(s) where Ca2+o
binds to the CaR is yet not fully clear, but it has recently been
suggested that one potential binding pocket resides within the
cleft between the two lobes in each receptor monomer (15).
Most likely the ECD of each CaR monomer contains more than
one binding sites for Ca2+o, because the Hill coefficient for the
activation of the CaR by calcium is 3-4, suggesting positively
cooperative interactions among at least this number of binding
sites within the dimeric CaR. The TMD seems also to be in-
volved in Ca2+o-sensing, as a mutated CaR expressed without
the ECD also responds to Ca2+o and other polyvalent cations
(16, 17). The receptor carries two protein kinase A (PKA) and
five protein kinase C (PKC) phosphorylation sites (Fig. 1) (18).
The PKC sites participate in a negative feedback mechanism,
as phosphorylation of the PKC sites inhibits activation of phos-
pholipase C (PLC) by the CaR, a major downstream mediator
of the receptor’s biological responses. PLC is upstream of
CaR-mediated activation of PKC. Before the CaR was cloned,
it was recognized that activation of parathyroid chief cells with
high calcium inhibited hormone-dependent cAMP production
and induced PLC activity and thereby IP3 production, suggest-
ing that the CaR activated Gαq as well as Gαi/o (19, 20). The
ICD binds the scaffolding proteins, filamin-A and caveolin-1
(the CaR is immunoprecipitated by anti-caveolin antibodies,
but direct binding of caveolin-1 to the CaR has not been
shown) (21, 22), both of which also bind to signaling partners
activated by the CaR. Binding to filamin-A was recently report-
Figure 1 - Predicted topological features of the extracellular Ca2+-sens-
ing receptor cloned from human parathyroid glands in a schematic
drawing. The extracellular domain contains approximately 600 amino
acids, and the transmembrane domain and intracellular domain each
contain approximately 200 amino acids. Also illustrated are the protein
kinases C (PKC) phosphorylation sites, N-glycolysation sites and con-
served cysteines.
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ed to induce protection of the CaR from degradation (23); this
may explain why some authors have found that the CaR does
not internalize secondary to ligand binding.
A plethora of intracellular signaling pathways of the CaR have
been discovered utilizing a heterologous system of human em-
bryonic kidney (HEK) cells with or without stably transfected
CaR (HEK-CaR). Most of these intracellular signaling pathways
have also been shown to be active in CaR-mediated signaling
in other cells naturally expressing the CaR. In parathyroid cells
and HEK-CaR cells, the CaR activates phospholipases (PL)
A2, C, and D (24). PLC produces IP3, which in turn activates
the IP3 receptor in the membrane of the endoplasmic reticulum
(ER), resulting in release of calcium from its internal stores
within the ER; the resultant release of calcium into the cytosol
produces spikes in the cytosolic free calcium concentration
(Ca2+i). An initial step in the production of polyphosphoinosi-
tides is the activation of phosphoinositol 4-kinase, which con-
verts PI to PI-4P. The CaR activates phosphoinositol 4-kinase
through Gαq in parallel with activation of PLC in HEK-CaR cells
(25). Another important class of intracellular signaling path-
ways linked to the CaR is the mitogen-activated protein kinas-
es (MAPKs). MAPKs are activated by phosphorylation by their
respective upstream kinases. MAP kinases are important intra-
cellular signaling pathways that often act through changes in
gene transcription, e.g., in the regulation of the cell cycle. But
MAPKs can also regulate events close to the cell membrane,
such as secretion of peptides and activity of potassium chan-
nels. We have shown that the CaR in HEK-CaR cells and
parathyroid cells activates MAPKs (26). Soon after, Hand-
logten et al. also showed that the CaR promotes MAPK phos-
phorylation in HEK-CaR cells; as a control, they used HEK
cells stably transfected with a dominant-negative CaR
(Arg796Trp) (27). They also showed that the CaR activates
PLA2 through Gαq, PLC, calmodulin, and calmodulin-depen-
dent kinase, but not through Gas or MAPK in HEK-CaR cells.
The reasons underlying the differences in the results of these
two studies regarding the role of MAPK in PLA2 activation re-
mains to be clarified. In cells expressing the CaR at a lower
level than parathyroid cells and HEK-CaR cells, such as testic-
ular cancer cells, MAPK and phosphatidylinositol 3-kinase (PI-
3kinase), a classical prosurvival pathway, have been found to
be activated by the CaR (28, 29). 
Agonists of the calcium-sensing receptor
The CaR is a promiscuous receptor with many ligands. CaR ago-
nists are classified as type I or type II. Type I are direct agonists,
whereas type II are allosteric modulators, i.e., they require the
presence of calcium to activate the CaR; the type II modulators
left-shift the calcium dose-response curve. The type I ligands are
all polycations, both inorganic and organic. Inorganic di- and triva-
lent cations have been tested for their potency on the CaR, and
they rank as follows: Gd3+ŽLa3+>>Ca2+=Ba2+>Sr2+>Mg2+ (6, 30).
The best known type I organic polycationic CaR agonists are
neomycin, spermine, and amyloid β-peptides (31-33).
Neomycin and gadolinium are often used to show that an effect
of Ca2+o is likely to be mediated through the CaR, although
they are by no means specific for the CaR. Slight changes in
Ca2+o (50-100 micromolar) regulate CaR activity, but the affini-
ty of the CaR for calcium is far lower than that of other GPCRs
for their ligands. The low affinity of the CaR, when taken within
the context of the millimolar levels of calcium within bodily flu-
ids as well as the steepness of the relationship between Ca2+o
and CaR activity, make the CaR a perfect “calciostat” for in-
forming the cell of the exact concentration of Ca2+o within the
immediate vicinity of its plasma membrane. The Hill coefficient,
a measure of how well the receptor responds to small changes
in agonist concentration, is 3 to 4 in HEK-CaR cells (34), as
noted above. In dispersed parathyroid cells in vitro, the CaR is
even more sensitive: PTH secretion is maximal at 0.75 mM and
minimal just below 2 mM ionized Ca2+o (35). HEK-CaR cells as
well as other cells that, in general, express the CaR at lower
levels than the parathyroid chief cells, such as primary testis
leydig cancer cells, have higher EC50 values (~3-4 mM) (34,
36). 
As mentioned earlier, type II agonists are allosteric modulators
of the CaR, i.e., they potentiate the effect of Ca2+o on the CaR,
and comprise two groups: small molecule drugs and amino
acids. Drugs allosterically activating the CaR are termed “cal-
cimimetics” (37). NPS R-467, R-568 and AMG 073 have all
been used in experimental studies and clinical trials and lately
in the treatment of uremic secondary hyperparathyroidism (38-
42). AMG 073 is the drug of choice in the clinic, because NPS
R-467 and NPS R-568 are degraded by a cytochrome P-450
enzyme, CYP2D6 (Amgen, unpublished data). Five to seven
percent of the population expresses CYP2D6 as an isoenzyme
with reduced enzymatic activity, thereby resulting in higher
blood level of these drugs in this segment of the population.
The calcimimetic binds to the TMD and enhances the apparent
affinity of the CaR for calcium. Some L-amino acids have also
been found to be type II agonists of the CaR, whereas the re-
spective D-amino acids are several-fold less potent in stimulat-
ing the receptor (43, 44). This CaR’s capacity to respond to
both extracellular calcium and L-amino acids may enable it to
act as a receptor that senses nutrients in the gut, for example.
Most likely, the amino acids bind to the CaR in the ECD, utiliz-
ing a binding pocket homologous to those binding glutamate
and GABA in the mGluRs and GABAB receptors, respectively
(45). This may be of pharmacological relevance, as the cal-
cimimetic NPS R-467 and L-phenylalanine have synergistic ef-
fects in activating the CaR (46). Lastly, another type of phar-
macological agent acting on the CaR is the calcilytics, which
antagonize the action of Ca2+o on the receptor, which may be
of use in osteoporosis treatment as it stimulates endogenous
PTH secretion.
Physiology
For the body it is crucial that the level of Ca2+o is maintained
within a narrow range (1.1-1.3 mM). Both very high and very
low levels of Ca2+o are dangerous and can be life-threatening.
Even minute changes in Ca2+o, in the range of a few percent,
lead to immediate physiologic responses, including altered
PTH secretion, that restore Ca2+o to its normal level. Rapid
changes in Ca2+o are more dangerous than slowly developing
ones; therefore the rapidity of the PTH response is essential.
Parathyroid hormone (PTH), calcitonin, and 1,25(OH)2D3 are
the three major Ca2+o-regulating hormones, the so-called
“calciotropic hormones” (47, 48). As mentioned above, there
is a crucial inverse relationship between Ca2+o and the calci-
um-elevating hormone, PTH – a relationship mediated by the
CaR (Fig. 2) (1, 35). There is a positive relationship between
Ca2+o and the release of calcitonin (CT), a Ca2+o-lowering
hormone; this feedback loop of calcium on CT secretion is al-
so mediated by the CaR (49). The rapidity of the secretory re-
sponses of PTH and CT to perturbations in extracellular calci-
um restores Ca2+o to its normal level within minutes to hours.
The CaR is now known to be expressed not only in the cal-
ciotropic hormone-secreting organs (parathyroid gland and C-
cells of the thyroid glands), but also in tissues that regulate
the extracellular calcium concentration by translocating calci-
um ions into or out of the bodily fluids: kidney and, at lower
levels, bone and intestinal cells. The presence of the CaR in
these tissues involved in Ca2+o homeostasis enables Ca2+o to
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act, in effect, as another Ca2+o-regulating hormone, e.g., as a
“first messenger”. Increases in the extracellular ionized calci-
um concentration stimulate the CaR to lower Ca2+o by pro-
moting CT secretion, increasing urinary calcium excretion and
inhibiting PTH secretion. In the remaining parts of this sec-
tion, we will briefly discuss the CaR’s known and potential
roles in three out of the four main organs involved in calcium
homeostasis: parathyroid gland, kidney and bone. For a re-
view of the localization and possible roles of the CaR along
the gastrointestinal tract, please see review by Hebert et al.,
2004 (50).
Parathyroid (PT) glands
The most important function of the CaR lies in the receptor’s in-
hibitory effects on PTH secretion. The CaR regulates the re-
lease of PTH, a key calcium-elevating hormone, and the steep
inverse sigmoidal relationship between Ca2+o and PTH was de-
scribed long before the CaR was cloned. Studies of Ca2+o-reg-
ulated PTH release in dispersed parathyroid cells are largely
limited to studies carried out within a matter of hours of isola-
tion of the cells, since these cells lose their expression of the
CaR on the cell membrane in a time-dependent manner (51,
52). The CaR is highly expressed on the cell surface of the
chief cells of the PT cells. Not much is known about the regula-
tion of its expression on the cell surface, but interestingly in
rats, the expression of the CaR in parathyroid and kidney was
upregulated by 1,25(OH)2vitamin D, while Ca2+o was without
effect (53). Another instance in which there is regulation of
CaR expression is in sheep that have undergone burn injury,
where there was upregulation of the parathyroid CaR in the
burned but not the sham animals. The authors also saw a re-
lated decrease in set-point for calcium suppression of PTH se-
cretion. This may contribute to post burn hypocalcemia and hy-
poparathyroidism (54) as well as to the hypocalcemia with in-
appropriately normal levels of PTH observed in patients se-
verely ill with inflammatory states. 
In bovine parathyroid cells, the CaR is situated on the cell mem-
brane within caveolin-rich membrane domains (21). Caveolae
are recognized as message centers where a variety of signaling
molecules are concentrated. A report found that CaR activation,
through the PKC pathway and, to a lesser extent, the PI-3K
pathway, increases ERK1/2 activity in normal parathyroid cells
(55); these signaling pathways seem to be involved in the mod-
ulation of PTH secretion by Ca2+o. 
Kidney: expression, function and regulation of the CaR
The kidney plays key roles in calcium homeostasis. The CaR is
widely expressed along nearly the entire nephron. The cellular
localization and apparent function(s) of the CaR seem to de-
pend upon the site of the nephron in which it is expressed (56).
We will now briefly describe the location of the CaR as well as
its functions in selected parts of the nephron. The expression
of the CaR along the nephron has been assessed using in situ
hybridization and reverse transcriptase-polymerase chain reac-
tion of micro-dissected nephron segments (8, 57). Subsequent-
ly, the cellular and regional distribution of receptor protein was
assessed by immunofluorescence microscopy (58). One over-
all point is that the polarity of the CaR varies along the nephron.
In the proximal tubule the CaR is expressed on the apical sur-
face of proximal tubular cells. In contrast, in the cells of the cor-
tical thick ascending limb (TAL), the CaR is expressed in the
basolateral membrane. Likewise basolateral staining for the re-
ceptor was also detected in medullary thick ascending limb,
macula densa, and the distal convoluted tubule. In the cortical
collecting duct, CaR immunostaining is present on some inter-
calated cells, and in the inner medullary collecting duct the re-
ceptor has predominantly an apical distribution. 
There have been relatively few studies addressing the factors
regulating the expression of the CaR in the kidney. A recent re-
port showed that in rat kidney, C-cell and parathyroid in vivo
and in a human proximal tubule cell line in vitro, CaR gene
transcription increased approximately two-old at 8 and 12 h af-
ter treatment with 1,25(OH)2vitamin D3 (59). This study charac-
terized vitamin D-responsive elements in each of the two pro-
moters that lie upstream of the CaR gene. Another research
group found no effect of a low phosphate diet on CaR expres-
sion along the nephron (60). In contrast, Riccardi et al. showed
in vivo in rats that CaR protein in the proximal tubule was
downregulated by a low phosphate diet as well as by treatment
with PTH. Therefore, CaR expression in the proximal tubule of
the rat kidney is regulated by vitamin D and PTH and, perhaps,
by dietary phosphate (61). The only other study on the regula-
tion of the expression of the CaR along the nephron showed
that the level of CaR protein in purified apical membrane endo-
somes isolated from inner medullary collecting ducts was re-
duced in rats made hypercalcemic by administration of vitamin
D (62). The functions of the CaR along the nephron are in
brief: 1) to diminish PTH’s inhibitory effect on renal phosphate
reabsorption in the proximal tubule (63); 2) to inhibit renal calci-
um excretion in the cortical thick ascending limb of the loop of
Henle (64); and 3) to reduce urinary concentrating capacity in
the inner medullary collecting duct (65). For an extended re-
view, please see Tfelt-Hansen et al., 2005 (66). 
Bone
It is well described that Ca2+o inhibits osteoclast formation and
activity and increases osteoblastic activity. The first evidence of
a G protein-coupled, cation-sensing mechanism in osteoblasts
came shortly after the cloning of the CaR (67). Subsequently,
some (68-74), but not all (75, 76) reports have found the CaR to
be expressed in osteoblasts. A very interesting study showed
that osteoblasts from CaR knock-out mice still had a promito-
genic response to Ca2+o (77), indicating the presence of a calci-
um-sensing mechanism other than the CaR. This mechanism
could potentially be represented by the newly cloned GPRC6C
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Figure 2 - Sigmoidal relationship between the blood Ca2+ and serum
PTH in the normal state, in autosomal dominant hypoparathyroidism
(ADH), and in familial hypocalciuric hypercalcemia (FHH) as well as the
therapeutic effect of the calcimimetic (shifting set-point to the left) and
the calcilytic (shifting set-point to the right). Set-point is defined as the
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(4). One possible mechanism, besides the new receptor
GPRC6C, underlying some of the calcium-induced effects in os-
teoblasts is the calcium-binding intracellular protein, calcyclin
(78). The CaR is also expressed in articular and hypertrophic
chondrocytes. Using a type II CaR agonist in organ culture (fetal
rat metatarsal bones) for bone growth, Wu et al. (79) showed
that the CaR regulates growth plate chondrogenesis and stimu-
lates longitudinal bone growth. 
The CaR is expressed on some osteoclasts (69, 80, 81) and
their precursors (82). In addition to lowering osteoclast forma-
tion and activity, high calcium has been shown to augment the
apoptosis of osteoclasts (83). The calcimimetic AMG 073, a
type II agonist of the CaR, however, produced none of the ef-
fects of calcium on osteoblast proliferation or osteoclast forma-
tion and resorption in one study (84). One possible mechanism
for calcium-sensing in osteoclasts other than the CaR is a plas-
ma membrane, ryanodine-like receptor that couples to eleva-
tions in intracellular calcium (85). Thus, while the CaR and oth-
er calcium-sensing mechanisms may play a role in bone, fur-
ther studies are clearly needed to resolve the discrepancies in
the studies to date. 
Genetic changes leading to FHH, NSHPT, and ADH
The CaR has been found to be responsible for the majority of
cases of FHH, NSHPT, and ADH, and around 200 mutations
have been reported in patients with these disorders (CaR
Database at website http://www.casrdb.mcgill.ca/). The muta-
tions are mainly missense, but also splice-site, nonsense, dele-
tion, and insertion mutations. The mutations are mainly found
in the extracellular domain and are found throughout exons 2
to 7 and in introns 2 and 4 of the CaR gene (5, 86-89). 
Familial hypocalciuric hypercalcemia (FHH) [OMIM # 145980
(90)]
Clinical aspect of FHH
FHH is a benign state of hypercalcemia. The diagnosis of FHH
is made in a patient with a family history of mild to moderate
hypercalcemia averaging approximately 2.75 mM (total calci-
um), with an inappropriately low rate of urinary calcium excre-
tion. While benign and asymptomatic hypercalcemia is typical
of most FHH families, two families have been found to have
calcium concentrations that average 3.13 and 3.35 mM, caus-
ing a neonatal severe hyperparathyroid-like state in some af-
fected infants (34, 91). Since the condition is benign in most
cases, patients with FHH are often undiagnosed until a routine
blood sample shows an unexpectedly high serum calcium level
or family screening is done due to the birth of a child with NSH-
PT (92). Patients with FHH usually have normal PTH levels,
despite the hypercalcemia, although in some cases the PTH
levels are elevated (86, 93). 
The hypercalcemia in FHH, in the setting of a normal PTH that
is inappropriately high compared to the serum calcium concen-
tration, reflects a new, right-shifted set-point for Ca2+o-regulated
PTH secretion (94, 95) (Fig. 2). A key finding is the relative
hypocalciuria despite the hypercalcemia, which represents “re-
sistance“ of the kidney to the normally hypercalciuric action of
hypercalcemia and is analogous to the resistance of PTH secre-
tion to the suppressive effect of high calcium in this condition.
Interestingly, treatment with a loop diuretic enhances renal cal-
cium excretion in hypoparathyroid patients with FHH (96). This
finding points towards an important role of the TAL – the site of
action of this class of diuretics – in the abnormal renal handling
of calcium in FHH. The best distinction between FHH and other
forms of hypercalcemia is often made by determining the ratio
of calcium clearance to creatinine clearance (Ca/Cr). A value
below 0.01 is found in about 80% of cases of FHH, while a simi-
lar proportion of cases of primary hyperparathyroidism caused
by hyperplasia or parathyroid adenoma have values higher than
this (97). Another clinical hallmark is the ability of patients with
FHH to concentrate their urine normally, in contrast to patients
with primary hyperparathyroidism, in whom maximal urinary
concentration in response to dehydration is modestly dimin-
ished (98), although this finding is not used diagnostically. Pa-
tients with FHH typically have serum magnesium levels that are
in the upper part of the normal range or mildly elevated. Lastly,
while distinguishing FHH from primary hyperparathyroidism can
in many cases be straightforward, a recent study investigating
the genetic background of familial isolated hyperparathyroidism
found that four of 22 unrelated probands had an inactivating
mutation in the CaR, while five had mutations in the multiple en-
docrine neoplasia 1 gene (99). Thus the clinician should keep
FHH in mind as an important and underdiagnosed cause of iso-
lated familial hyperparathyroidism (99, 100), Furthermore this
study may implicate a new less stringent perception of the
range of phenotypes that may be encountered in patients with
functional significant mutations in the CaR. 
The clinical presentation of FHH, however, is not always straight-
forward. A family has been described that was serendipitously
found to have hypercalcemia caused by an inactivating FHH mu-
tation, and in whom hypercalciuria or even renal stone formation
was found in some family members (86). Subtotal parathyroidec-
tomy appeared to provide long-term remission of the hypercal-
cemia and hypercalciuria in this family, indicating that parathy-
roid surgery may be appropriate in an occasional FHH family. In
two recent papers, single and multiple parathyroid adenomas
were found in several patients with FHH (86, 101). Some au-
thors have suggested that a histological finding of parathyroid
lipohyperplasia, which has been found in some cases of FHH
subjected to parathyroidectomy, is indicative of inactivating mu-
tations of CaR (102, 103). 
Thus overall FHH is an asymptomatic form of hypercalcemia,
but in rare cases it may present as more severe hypercal-
cemia. Since the condition is generally so benign and, except
in rare cases (see above), only total parathyroidectomy is cura-
tive, the great majority of these patients should be followed
without intervention. In FHH patients with symptomatic hyper-
calcemia, the new calcimimetics might in theory be the optimal
treatment; this approach, however, has not yet been reported.
Genetic aspects of FHH
Functionally important mutations in the CaR gene lead to
changes in the amino acid sequence of the CaR protein. The
altered amino acid sequence in FHH or NSHPT causes a loss-
of-function of the CaR that shifts the set-point of Ca2+o-regulat-
ed PTH secretion to the right (Fig. 2). In 1972, Foley et al.
(104) first characterized the hereditary condition later defined
as familial hypocalciuric hypercalcemia (FHH). The predomi-
nant locus of the FHH disease gene was mapped by linkage
analysis to the long arm of chromosome 3 (band q21-24) with
the use of the hypercalcemic (90) phenotype in four large FHH
families (105). FHH is not always linked to chromosome 3q. In-
terestingly, in two families, a clinical picture similar to FHH was
linked to the short and long arms of chromosome 19 (106,
107), respectively, one called the Oklahoma variant (107). This
may explain a minority of the ~30% of FHH cases in which no
mutation in the CaR gene is identified. The remainder of these
latter cases are presumed to harbor mutations in regulatory re-
gions of the gene controlling its expression, but this has not
been directly shown.
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The first three different missense mutations in the CaR gene in
the affected members of three unrelated families were reported
during the same year as the cloning of the receptor in 1993
(108). Since the initial discovery of these mutations in the CaR
gene, around 200 additional mutations have been character-
ized. Most are unique to individual families, although some un-
related kindreds have identical mutations (e.g., gly552arg) (5,
108). The majority of the mutations are missense and reside in
the ECD or TMD of the receptor. An unusual type of mutation
was discovered in a family with FHH, where the mutation was
found in the acceptor splice site at position-1 of intron 2 of the
CaR gene, causing a frame shift. The frame shift produced a
truncated protein of 153 amino acids (87). The mRNA for the
CaR was stable, but the truncated protein was never found on
the cell membrane, in large part because of lacking any trans-
membrane domains. It is likely that the mutant CaR protein is
degraded due to abnormal intracellular trafficking. Different
mutations can lead to distinct phenotypes: a mutant receptor
can exert a dominant-negative effect on the remaining normal
CaR receptor, making the phenotype more severe (91). The
normal CaR functions as a homodimer; accordingly, the het-
erodimerization of a non- or poorly functional mutant protein,
which nevertheless reaches the cell surface, with the wild-type
CaR can partially inactivate the heterodimeric receptor com-
plex (14, 109, 110). A dominant-negative action reflects the
specific properties of the mutant receptor protein on the cell
membrane. With a mutation producing a dominant negative ac-
tion, normally functioning, wild type CaR homodimers would
comprise only about one-fourth of all the receptors (there
would be a theoretically expected ratio of 1:2:1 of mutant ho-
modimer, wild-type-mutant heterodimer, and wild-type homod-
imers, respectively). Inactivating mutations (e.g., deletions) in
the CaR gene may not form heterodimers but simply reduce
the number of normally functioning CaRs expressed on the cell
surface, producing so-called haploinsufficiency, which results
from a decrease in receptor expression/activity owing to the
loss of one CaR allele. Two mutant CaRs with mutations at
amino acid residues 11 and 13, respectively, have been char-
acterized to have low cell surface expression in human embry-
onic kidney cells, most likely because the missense mutations
were situated within the signal peptide of the ECD, which is re-
quired for proper targeting of the nascent receptor polypeptide
to the lumen of the ER (111). One thing that should be kept in
mind when evaluating the literature where different mutations
have been characterized in vitro is that the cells used for the in
vitro experiments are very different from the chief cells of the
parathyroid glands or the kidney cells. Thus the experimental
data should be seen as representing only an approximation of
how the receptors function when expressed endogenously in
the cells that are involved in maintaining calcium homeostasis.
Neonatal severe primary hyperparathyroidism (NSPHT) [OMIM
239200 (90)]
Clinical aspects of NSPHT
Neonatal severe primary hyperparathyroidism in most cases
presents within the half year of life. The infant has severe,
symptomatic hypercalcemia driven by PTH, as well as bony
changes characteristic of hyperparathyroidism. Infants with
NSHPT can display hypotonia, polyuria, dehydration, and fail-
ure to thrive. The hallmark of the disease is the associated hy-
perparathyroid bone disease. This bone disease often leads to
multiple fractures. Fractures in the ribs may produce a “flail
chest” syndrome that causes respiratory difficulties, since the
affected infant will have decreased ability to expand its chest
wall and thereby generate the negative intrathoracic pressure
needed for inspiration. The mass of the parathyroid glands in
NSHPT is often increased dramatically. Pathological investiga-
tion reveals chief cell hyperplasia. Biochemical analysis re-
veals hypercalcemia, hyperparathyroidism, and relative
hypocalcuria (112). Levels of serum total calcium range from
moderately elevated (e.g., 3-3.25 mM) to as high as 7.7 mM in
the most severe cases (97). PTH levels are often observed to
be 10-fold higher than the upper limit of normal. Early diagno-
sis is key, as untreated NSHPT can be a devastating neurode-
velopmental disease that is lethal when not treated surgically
(112). As mentioned above, patients with the most severe
forms of NSHPT develop ribcage deformities, rachitic changes,
skeletal undermineralization, and fractures (113, 114). There is
a substantial mortality described in the literature; therefore,
treatment for the disorder in its severe form is total parathy-
roidectomy. However, lately a wider clinical spectrum for the
condition has become apparent; and the growing availability of
genetic testing of the CaR gene has documented that some in-
fants have milder hyperparathyroidism and a distinctively less
severe clinical presentation and natural history. This latter form
of the disease has been termed neonatal hyperparathyroidism
(NHPT), and parathyroidectomy may not be the only treatment
of choice in infants with this condition. Reports have document-
ed that patients who would have been expected to have the
clinical presentation of NHPT or NSHPT have survived with
their condition undetected into adulthood, when they were
found by routine screening to have PTH-dependent hypercal-
cemia. This may be due to heterozygous or homozygous FHH
mutations, e.g., a 35-year-old woman with two copies of the
missense mutation pro39ala from related parents. She was
clinically asymptomatic, with a serum calcium concentration of
3.75 to 4.25 mM (115). Another patient with homozygous inac-
tivating mutations was likewise not diagnosed until adulthood
(102). In these patients the use of the calcimimetics in theory
might represent a means of lowering the serum calcium con-
centration and determining whether the patient derived any
symptomatic benefit, thereby potentially providing a long term,
effective medical therapy.
Genetic aspects of NSHPT
NSHPT is an autosomal recessive disease, which means that
the CaR gene from both the parents is mutated (e.g., homozy-
gous FHH). Pollak et al. reported that in 11 families with FHH
consanguineous unions produced four children with NSHPT
(116). NSHPT, however, is quite uncommon among FHH fami-
lies as a whole. In one case of NSHPT, two different mutations
– one a mutation in exon 4 from the father and the second a
mutation in exon 7 from the mother – were reported to cause
the disease, e.g., owing to compound heterozygosity in the
proband (117). Theoretically NSHPT can be the result either
of a mutated allele of the CaR gene arising from two existing
FHH kindreds or from a de novo mutational event, with or
without the inheritance of a parental mutant allele (89). Fur-
thermore a genetic study of a girl with phenotypic NSHPT and
her family showed a single abnormal allele (present in exon 6,
Gly552Arg) in her CaR gene, while her sister, who had the
same genotype, had phenotypic FHH (110). Therefore, the fac-
tors contributing to the development of NSHPT are still only
partly understood. 
Autosomal dominant hypoparathyroidism (OMIM) [#601298
(90)]
Clinical aspects of ADH
Patients with this inherited form of hypocalcemia are often clini-
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cally asymptomatic, similar to most patients with FHH. Some
patients can have seizures, neuromuscular irritability and calci-
fication of the basal ganglia. A biochemical hallmark of the dis-
ease is, of course, the mild to moderate hypocalcemia, with
serum PTH levels that are inappropriately within the lower half
of the normal range or frankly subnormal (e.g., rather than re-
sponding vigorously to the hypocalcemia, as would a normal
parathyroid gland) (118). They often have relative or absolute
hypercalciuria, with normal or elevated levels of urinary calcium
excretion, respectively, despite the low serum calcium. Their
renal calcium excretion has been found to be higher than that
of patients with typical hypoparathyroidism in some studies,
and, analogous to the diagnosis of FHH, a high urinary Ca/Cr
ratio may be better than hypocalcemia alone for differentiating
ADH from primary hypoparathyroidism. However, not all stud-
ies showed this difference in the level of urinary calcium excre-
tion between idiopathic hypoparathyroidism and ADH (119,
120). Febrile episodes may unmask the disease; hence in
some cases, and not infrequently during febrile episodes, pa-
tients with ADH may present with symptoms of hypocalcemia
as well as seizures. It is important to prevent renal complica-
tions such as nephrocalcinosis, nephrolithiasis, and renal im-
pairment. These renal complications are caused primarily by
the hypercalciuria. The renal complications are usually seen in
the setting where the clinician has tried to fully correct the low
serum calcium with calcium and vitamin D treatment. Therapy
with calcium supplements and vitamin D metabolites should be
administered only to patients with symptomatic ADH, and the
aim should be to increase the serum calcium concentration on-
ly to a level that renders the patient asymptomatic. Renal out-
put of calcium should be monitored in treated patients to lower
the risk of urinary complications (121). The development of the
calcilytic could, in theory, provide an optimal treatment of symp-
tomatic ADH patients. These agents would be expected to shift
the set-point for calcium-regulated PTH secretion to the right
and to reduce the renal excretion of calcium at any given
serum calcium concentration. 
Genetic aspects of ADH
ADH is a rare diagnosis, although in index cases it may repre-
sent a sizeable proportion of cases of idiopathic hypoparathy-
roidism, accounting for as many as a third of such cases
(122). The mechanism behind the disease is the presence of
an activating or gain-of-function mutation of the CaR gene that
changes the set-point of Ca2+o-regulated PTH secretion to the
left and lowers renal reabsorption of calcium (Fig. 2). Soon af-
ter the cloning of the CaR in 1994, Finegold et al. (123) showed
that the disease is linked to a locus on chromosome 3 q13 –
the same region on the chromosome that contains the gene
for the CaR. In the same year, a heterozygous missense mu-
tation, Glu127Ala, was identified as a cause of ADH in an un-
related family (118). Since these first reports, around 60 mis-
sense mutations have been characterized in families with ADH
(CaR Database at website http://www.casrdb.mcgill.ca/). Most
of these missense mutations are present within the ECD and
TMD of the CaR. Expression of several of the known activat-
ing mutations of the CaR in HEK293 cells has shown that the
mutations cause a clear left-shift in the activation of the CaR
protein by Ca2+o and only rarely produce constitutive activation
of the receptor (34, 121, 122, 124, 125). A recently described
and novel type of activating mutation has been identified in
France (122). The affected family members have a large dele-
tion of 181 amino acids within the C-terminus of the CaR. Sur-
prisingly, one family member was homozygous for the muta-
tion but showed a phenotype similar to that of the heterozy-
gous family members. These studies reveal that one mutated
allele may be sufficient to induce a maximal shift in the set-
point of Ca2+o-regulated PTH secretion, and that a second mu-
tated allele does not change the biochemical properties of the
receptor dimers any further (e.g., perhaps the mutant CaR
monomers exert a “dominant positive” effect in mutant-wild
type heterodimers vs. mutant homodimers). It should be em-
phasized, however, that the biochemical phenotype of a pa-
tient homozygous for an activating mutation has only been
shown in this one report. Examination of the family in another
novel study revealed a mutation that had occurred de novo in
the proband. The heterozygous mutation was at codon 129
(TGC to AGC), causing a change of a cysteine to a serine
(Cys129Ser) (126). This cysteine is involved in dimerization of
the CaR, and these studies may suggest that this cysteine
constrains the receptor in its inactive state. 
Autoimmune diseases
Autoimmune acquired forms of hypo- and hypercalcemia anal-
ogous to ADH and FHH, respectively, have recently been de-
scribed. While these conditions are rare, we will briefly review
this literature, as the diseases are important to recognize in the
differential diagnosis of the diseases of calcium homeostasis
described above. 
Anti-CaR antibodies and PTH-dependent hypercalcemia
Kifor et al. (127) identified autoantibodies to the CaR in four
patients with other autoimmune conditions (e.g., Hashimoto’s
thyroiditis and sprue), who had a clinical picture resembling
that of FHH. In this study, the patients’ sera were found to stim-
ulate PTH secretion and to inhibit high calcium-stimulated inos-
itol phosphate accumulation and MAPK activation, most likely
by antibody-mediated inhibition of the CaR, since the patients
were shown to harbor anti-CaR antibodies. Further studies in
larger cohorts of patients are needed to determine the inci-
dence of autoimmune FHH with various types of autoimmunity
and PTH-dependent hypercalcemia.
Anti-CaR antibodies and hypoparathyroidism
Acquired hypoparathyroidism (AH) is a disease with hypocal-
cemia caused by low PTH secretion with no known cause
(e.g., hypomagnesemia or prior neck surgery). AH was the
first disease that was linked to autoimmunity to the CaR. In
an early study, Blizzard et al. reported autoantibodies to the
parathyroid glands in 1967. They found that 38% of 74 pa-
tients with AH were positive for autoantibodies to the parathy-
roid, as compared with only 6% of 245 healthy control sub-
jects (128). The autoantibodies to the parathyroid glands in
patients with sporadic, adult-onset hypoparathyroidism were
directed at the cell surface of human parathyroid cells and
were reported to inhibit PTH release in a later study (129). Li
et al. (130) subsequently reported that 14 of 25 patients with
AH had antibodies directed at the CaR, whereas none of the
control group of 50 patients with various other autoimmune
diseases and 22 normal controls had antibodies to the recep-
tor. In a recent study, Kifor at a. described two patients with
hypoparathyroidism, who had anti-CaR antibodies that acti-
vated the receptor as evaluated by simulation of inositol
phosphate accumulation and MAPK activity and inhibition of
PTH secretion (131). Two additional studies have found con-
flicting results regarding the prevalence of anti-CaR antibod-
ies among patients with autoimmune hypoparathyroidism. A
recent study examining 90 patients with autoimmune polyen-
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docrine syndrome type 1 found no autoantibodies against the
CaR (132). In another study of 51 patients with idiopathic hy-
poparathyroidism – most of whom had isolated hypoparathy-
roidism – and 45 healthy controls, 49% of the patients had
serologic evidence of organ-specific autoimmunity to the CaR
protein (133). The paper showed an association between au-
toimmune antibodies to the CaR and the HLA-DR, implying
an autoimmune component to the disease. Of note in this re-
gard, the two patients in the study of Kifor et al. who had acti-
vating autoantibodies to the CaR also had Addison’s and
Graves’ disease, respectively, further supporting the hypothe-
sis of an autoimmune disease. Whether the difference be-
tween these studies reflects a difference in the incidence of
anti-CaR antibodies between patients with type 1 APS and
those with isolated hypoparathyroidism or is due to other fac-
tors remains to be clarified.
Summary and Future Issues
A significant component of the hereditary diseases of calcium
homeostasis, particularly those with evidence of abnormal
Ca2+o-sensing, have been shown to be caused by mutations in
the calcium-sensing receptor. The CaR is a membrane bound
7TM receptor expressed in all of the tissues regulating extra-
cellular calcium homeostasis. The CaR “senses” even minute
(on the order of a few percent) changes in the level of calcium
in the blood and acts, therefore, as the body’s “calciostat”. The
CaR, in turn, modulates the functions of the cells expressing it
so as to restore the level of blood calcium to normal. CaR-me-
diated regulation of the secretion of PTH plays a particularly
important role in calcium homeostasis, because it directly or
indirectly modulates the functions of all of the tissues involved
in regulating blood calcium. Patients with loss-of-function mu-
tations in the CaR gene display a form of hypercalcemia that
is accompanied by relative hypocalciuria. In its heterozygous
form, with one mutated allele, it is a benign form of hypercal-
cemia. In its homozygous form, with both CaR alleles mutated,
the hypercalcemia may be fatal if left untreated. Gain-of-func-
tion mutations leads to an often benign state of hypocalcemia
with relative hypercalciuria, called ADH. In the future it would
be interesting to collect detailed clinical data in large cohorts
in multicenter studies to investigate possible implications of
the altered sensitivity of the CaR towards calcium in these pa-
tients as well as the resultant altered levels of serum calcium.
This may be even more important than previously thought, as
the CaR is now known to be functionally expressed in many
organs, such as the brain, breast, cardiovascular system and
intestine (66, 134), that are not known to participate in sys-
temic calcium homeostasis. Lastly, symptomatic patients may
benefit from the new CaR modulators, calcimimetics and calci-
lytics. 
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